Nova Eye Medical (ELXMF) Stock Price, News & Analysis

Company Overview

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It offers iTrack, a glaucoma surgical device to reduce intraocular pressure in adult patients with open-angle glaucoma; iTrack Advance, a canaloplasty microcatheter; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.

Key Stats

• Today's Range: $0.10 to $0.10
• 50-Day Range: $0.10 to $0.10
• 52-Week Range: $0.10 to $0.19
• Volume: N/A
• Average Volume: 75,600 shs
• Market Capitalization: N/A
• P/E Ratio: 13.70
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ELXMF Stock Analysis - Frequently Asked Questions

How have ELXMF shares performed this year?

Nova Eye Medical's stock was trading at $0.10 at the beginning of 2025. Since then, ELXMF shares have increased by 0.0% and is now trading at $0.10.
View the best growth stocks for 2025 here.

How do I buy shares of Nova Eye Medical?

Shares of ELXMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 6/25/2025
• Next Earnings (Estimated): 8/25/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ELXMF
• CIK: N/A
• Web: www.ellex.com
• Phone: 61 8 7074 8200
• Fax: N/A
• Employees: 301
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 13.70
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A